阿帕替尼对Her2阴性晚期胃癌患者的治疗效果及毒副作用分析

目的:探究Her2阴性晚期胃癌患者采用阿帕替尼进行治疗的疗效及毒副作用。方法:按照不同治疗方法将本院就诊的Her2阴性晚期胃癌患者分为阿帕替尼组(AP组)和替吉奥组(TI组),各46例，分析比较两组患者的临床疗效、生活质量、毒副作用及远期疗效。结果:治疗后，AP组11例、TI组6例患者出现部分缓解，AP组患者RR、DCR数值明显比TI组高(P<0.05);AP组患者生活质量明显优于TI组(P<0.05)。AP组和TI组患者均出现血小板减少、蛋白尿、肝功能异常等不良反应，但未出现Ⅳ级毒副作用，其中AP组患者高血压、血小板减少的发病率分别为63.52%、76.73%,TI组患者发病率分别为62.45%、78.11%, AP组出现毒副作用的患者人数与TI组比较无明显差异(P>0.05)。随访3年结果显示，AP组患者3年生存率为10.86%,TI组患者为0,AP组患者总生存率明显高于TI组(P<0.05)。结论:阿帕替尼对Her2阴性晚期胃癌患者的临床疗效及远期治疗效果较佳，虽然治疗后也会出现一定的毒副作用，但与替吉奥治疗后出现的毒副作用相近，且患者身体承受程度较佳。阿...

Therapeutic effect and toxicity of apatinib in patients with Her2-negative advanced gastric cancer

Objective: To explore the efficacy and toxic side effects of apatinib in patients with ADVANCED gastric cancer with Her2 negative. Methods: Patients with Her2 negative advanced gastric cancer in our hospital were divided into apatinib group (AP group) and Tigio group (TI group) according to different treatment methods, with 46 patients in each group. The clinical efficacy, quality of life, toxic side effects and long-term efficacy of AP group and TI group were observed and compared. Results: After treatment, partial remission occurred in 11 patients in the AP group and 6 patients in the TI group. RR and DCR values in the AP group were significantly higher than those in the TI group (P＜0.05). Compared with TI group, the quality of life in AP group was significantly better than TI group (P＜0.05). The AP group and TI group showed thrombocytopenia, proteinuria, abnormal liver function and other toxic and side effects, but there was no class ⅳ toxic and side effects. The incidence rates of hypertension and thrombocytopenia were 63.52 % and 76.73 % in the AP group, and 62.45 % and 78.11 % in the TI group, respectively. There was no significant difference in the number of patients with adverse effects between the AP group and the TI group (P＞0.05). The 3-year follow-up results showed that the 3-year survival rate of AP group was 10.86 %, and the 3-year survival rate of TI group was 0 %. The overall survival rate of AP group was significantly higher than that of TI group (P＜0.05). Conclusion: Apatinib has good clinical efficacy and long-term treatment effect in patients with ADVANCED GASTRIC cancer with Her2 negative. Although there are certain toxic and side effects after treatment, they are similar to those after treatment with gio, and patients' body tolerance is better. Apatinib can be used to treat advanced gastric cancer.